TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04026126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat Therapy Treatment
Description: Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
Study: NCT02645526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Woolen cap
Study: NCT02918994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LearningRx cognitive training
Description: A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
Study: NCT02754401

Intervention type: OTHER
Group type: OTHER
Intervention: 16 Items
Description: Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).

Intervention type: OTHER
Group type: OTHER
Intervention: 16 Items
Description: Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).

Intervention type: OTHER
Group type: OTHER
Intervention: PSI
Description: The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).

Intervention type: OTHER
Group type: OTHER
Intervention: PSI
Description: The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
Study: NCT04090086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
Study: NCT06364722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
Study: NCT01492361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin therapy
Description: Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin therapy
Description: Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
Study: NCT04375293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiome swabs
Description: Swabs for analysis of microbiome

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome swabs
Description: Swabs for analysis of microbiome

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome swabs
Description: Swabs for analysis of microbiome

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Microbiome swabs
Description: Swabs for analysis of microbiome
Study: NCT00977288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: atorvastatin
Description: atorvastatin tablet, 10mg, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: atorvastatin
Description: atorvastatin tablet, 10mg, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: atorvastatin
Description: atorvastatin tablet, 10mg, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: atorvastatin
Description: atorvastatin tablet, 10mg, once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: atorvastatin
Description: atorvastatin tablet, 10mg, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks
Study: NCT03858712

Intervention type: OTHER
Group type: OTHER
Intervention: Active Care Team Alert
Description: 2) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher).

Intervention type: OTHER
Group type: OTHER
Intervention: Passive Care Team Alert
Description: Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy.
Study: NCT01653665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leukine
Description: Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
Study: NCT04613830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
Study: NCT05390346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: The intervention programs consist of nutrition monitoring and diet intervention.
Study: NCT02974075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvage lymph node dissection
Description: Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
Study: NCT02624843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzyl Alcohol Lotion 5%
Description: White topical lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulesfia (benzyl alcohol lotion) 5%
Description: White topical lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White topical lotion
Study: NCT01717976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DISPO ED
Description: primary care based nurse telephone support
Study: NCT02402166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
Study: NCT00676871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
Study: NCT03312257

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multifocal D +2.50 add & 0.01% atropine
Description: Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
Study: NCT02972398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator of N-acetylcysteine
Description: Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
Study: NCT03089112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607+HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607+HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607+HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607+HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607+HGP1501
Description: Take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607+HGP1501
Description: Take it once per period
Study: NCT04799600

Intervention type: OTHER
Intervention: BRESCİA-COVİD Respiratory Severity Scale
Description: KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score
Study: NCT00719966

Intervention type: DRUG
Intervention: anastrozole
Description: Patients receive aromatase inhibition therapy.

Intervention type: DRUG
Intervention: exemestane
Description: Patients receive aromatase inhibition therapy.

Intervention type: DRUG
Intervention: letrozole
Description: Patients receive aromatase inhibition therapy.

Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: Endothelial function is measured

Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: Endothelial function is measured
Study: NCT03165448

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-operative USOS scale testing
Description: Patient has to self-report USOS questionnaire just before the procedure as main scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-operative SDPQ, MDAS and VAS testing
Description: Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: Post-operative doctor's reported USOS
Description: Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Re-testing 4-6 weeks later
Description: All the participants has to refill USOS questionnaire 4-6 weeks later.
Study: NCT02153398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 20 mg
Study: NCT02497456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up counselling
Study: NCT03044548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive supervision
Description:  Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle .
Study: NCT01345019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zoledronic acid
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (for the open-label treatment phase)
Description: Administered by subcutaneous injection once every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab (for the open-label treatment phase)
Description: Administered by subcutaneous injection once every 4 weeks.
Study: NCT02204969

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lithia water
Description: * Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~* Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Description: All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
Study: NCT00219297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study: NCT03273322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg qd
Description: 10mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg qd
Description: 15mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT
Description: Aspirin 75 mg qd + Clopidogrel 75 mg qd
Study: NCT01799681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an 8-week blended indoor-outdoor exercise program
Description: stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: an 8-week upper limb and hand exercise program
Description: upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
Study: NCT02833038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: the same bolus and infusion volumes of normal saline